Bioequivalence Study of Bedaquiline Fumarate Tablets in Healthy Chinese Subjects
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1515 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Man Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Antitubercular Agents, Diarylquinolines, Drugs, Generic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Bedaquiline fumarate tablets are a novel oral antimycobacterial drug. This study assessed the bioequivalence of a generic bedaquiline fumarate tablet compared to a reference tablet under fasting (n = 44) and fed (n = 24) conditions. Conducted as a single‐center, randomized, open‐label, 2‐sequence, crossover trial, 68 participants were randomly assigned to receive a 100‐mg dose of either the test or reference tablet, with a 42‐day washout period between doses. Blood samples were collected at prespecified time points from 0 hour (before administration) to 984 hours after administration. Plasma concentrations of bedaquiline were measured using a validated ultra‐performance liquid chromatography‐tandem mass spectrometry method. Safety was monitored throughout the study. Key pharmacokinetic parameters included maximum plasma concentration, area under the plasma concentration‐time curve (AUC) from 0 to 72 hours, AUC from time 0 to the last measurable concentration, AUC from 0 to 336 hours, and AUC from time 0 to infinity. The 90% confidence intervals for the geometric mean ratios of the test/reference formulations for maximum plasma concentration, AUC from 0 to 72 hours, AUC from 0 to 336 hours, AUC from time 0 to the last measurable concentration, and AUC from time 0 to infinity fell within the bioequivalence acceptance range of 80%‐125%. confirming bioequivalence between the 2 formulations in healthy Chinese volunteers. Moreover, a high‐fat diet can significantly elevate the exposure of bedaquiline. No serious adverse events occurred, and both formulations were well tolerated across all participants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Department, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China.
- Beijing Fuyuan Pharmaceutical Co., Ltd., Beijing, China.
- Class 211 of Anesthesiology, The First Affiliated Hospital of Nanchang University, Nanchang University, Jiangxi, China.
- Phase I Clinical Trial Ward, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Zitieren
APA
Yang, M., Pei, Y., Chen, C., Xi, J., Xia, Y., Zhang, S., Liu, H., & Li, A. (2025). Bioequivalence Study of Bedaquiline Fumarate Tablets in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1515
Vancouver
Yang M, Pei Y, Chen C, Xi J, Xia Y, Zhang S, et al. Bioequivalence Study of Bedaquiline Fumarate Tablets in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1515
BibTeX
@article{Yang2025,
author = {Yang, Man and Pei, Yingzi and Chen, Chen and Xi, Jian and Xia, Yue and Zhang, Shuyu and Liu, Huichen and Li, Aimin},
title = {Bioequivalence Study of Bedaquiline Fumarate Tablets in Healthy Chinese Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1515}
}
EUVIMED